Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Resmed Inc (RMD)

Resmed Inc (RMD)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
ResMed (RMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

ResMed (RMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

RMD : 161.39 (-1.82%)
After Yesterday's Rally of 1.31% Shares Could Potentially Pullback

Resmed Inc (NYSE:RMD) traded in a range yesterday that spanned from a low of $161.84 to a high of $164.45. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $161.98...

RMD : 161.39 (-1.82%)
ResMed Launches AirFit F30i CPAP Mask, Widens Client Base

ResMed (RMD) launches its first tube-up, full-face CPAP mask, thus completing its full-face mask portfolio.

CERN : 75.68 (+0.21%)
MDT : 120.97 (-0.10%)
RMD : 161.39 (-1.82%)
HAE : 110.06 (-4.80%)
ResMed Introduces AirFit F30i, Its First Tube-up Full Face CPAP Mask

ResMed (NYSE: RMD) (ASX: RMD) today introduced AirFit F30i, its first tube-up full face CPAP mask, rounding out the most complete full face mask portfolio on the market.

RMD : 161.39 (-1.82%)
RESMED ALERT: Bragar Eagel & Squire, P.C. is Investigating Certain Officers and Directors of ResMed, Inc. and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized shareholder law firm, is investigating potential claims against certain officers and directors of ResMed, Inc. (NYSE: RMD) on behalf of long-term stockholders....

RMD : 161.39 (-1.82%)
Robbins LLP Is Investigating the Officers and Directors of ResMed Inc. (RMD) on Behalf of Shareholders

Shareholder rights law firm Robbins LLP is investigating whether certain officers and directors of ResMed Inc. (NYSE: RMD) breached their fiduciary duties to shareholders. ResMed develops, manufactures,...

RMD : 161.39 (-1.82%)
ResMed to Report Second Quarter Fiscal 2020 Earnings on January 30, 2020

ResMed (NYSE: RMD) (ASX: RMD) today announced it plans to release financial and operational results for the second quarter of fiscal year 2020 on Thursday, January 30, 2020, after the New York Stock Exchange...

RMD : 161.39 (-1.82%)
SmarTrend Watching for Potential Pullback in Shares of Resmed Inc After 1.08% Gain

Resmed Inc (NYSE:RMD) traded in a range yesterday that spanned from a low of $157.01 to a high of $157.75. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $156.12...

RMD : 161.39 (-1.82%)
ResMed Announces Participation in the 38th Annual J.P. Morgan Healthcare Conference

ResMed (NYSE: RMD, ASX: RMD) today announced that Mick Farrell, chief executive officer, will present at the 38th Annual J.P. Morgan Annual Healthcare Conference on Monday, January 13, 2020, beginning...

JPM : 136.54 (-0.10%)
RMD : 161.39 (-1.82%)
NUVA vs. RMD: Which Stock Is the Better Value Option?

NUVA vs. RMD: Which Stock Is the Better Value Option?

NUVA : 77.31 (-0.73%)
RMD : 161.39 (-1.82%)
Strong Pipeline Aids Tandem Diabetes Despite Stiff Rivalry

Tandem Diabetes' (TNDM) products under development comprise AID systems, a next-generation hardware platform and connected (mobile) health offerings.

TNDM : 68.54 (-1.22%)
HAE : 110.06 (-4.80%)
RMD : 161.39 (-1.82%)
NUVA : 77.31 (-0.73%)
Product Launches Aid Intersect ENT (XENT) Despite Cost Woes

Intersect ENT (XENT) recently closes its ENCORE study, a small 50-patient open label program designed to evaluate the safety of the repetitive use of SINUVA.

XENT : 25.03 (-0.56%)
RMD : 161.39 (-1.82%)
HAE : 110.06 (-4.80%)
EYE : 35.57 (+1.51%)
Bruker (BRKR) Rides High on Strong Nano Sales, New Buyouts

Bruker (BRKR) is reaping solid synergy benefits from the acquisitions of Anasys, JPK and Alicona.

BRKR : 52.82 (-0.70%)
HAE : 110.06 (-4.80%)
RMD : 161.39 (-1.82%)
EYE : 35.57 (+1.51%)
Zimmer Biomet Hits New 52-Week High: What's Driving It?

Zimmer Biomet (ZBH) is optimistic about maintaining growth momentum on several recent positive developments.

HAE : 110.06 (-4.80%)
NUVA : 77.31 (-0.73%)
RMD : 161.39 (-1.82%)
ZBH : 149.51 (-0.97%)
Neogen (NEOG) Q2 Earnings & Revenues Miss, Margin Rises

Neogen Corporation (NEOG) disappoints investors with dismal second-quarter fiscal 2020 results. However, the Food Safety segment showcased a robust performance.

HAE : 110.06 (-4.80%)
NEOG : 69.97 (+0.16%)
RMD : 161.39 (-1.82%)
EYE : 35.57 (+1.51%)
6 MedTech Stocks That are Set to Beat the Market in 2020

Banking on the three key trends, we zero in on six MedTech stocks that are likely to deliver stellar performance in 2020.

TNDM : 68.54 (-1.22%)
MDT : 120.97 (-0.10%)
NUVA : 77.31 (-0.73%)
DXCM : 235.60 (+0.03%)
RMD : 161.39 (-1.82%)
WST : 156.55 (-0.43%)
CNMD : 108.68 (-0.62%)
GNC Holdings Launches Energy Drink With Natural Extracts

GNC Holdings (GNC) launches natural ingredient-based energy drink MAD PONY ENERGY.

HAE : 110.06 (-4.80%)
RMD : 161.39 (-1.82%)
GNC : 2.22 (+0.45%)
EYE : 35.57 (+1.51%)
Neogen's (NEOG) Soleris for EBAC Receives AOAC's Clearance

Neogen's (NEOG) Soleris test gets clearance from the AOAC, paving the way for efficient prevention of food contamination.

HAE : 110.06 (-4.80%)
RMD : 161.39 (-1.82%)
NEOG : 69.97 (+0.16%)
EYE : 35.57 (+1.51%)
Zimmer Biomet Focuses on Priority Areas Despite Pricing Woes

Zimmer Biomet (ZBH) is executing well within its priority areas like quality remediation, supply recovery efforts and product rollouts.

HAE : 110.06 (-4.80%)
ZBH : 149.51 (-0.97%)
RMD : 161.39 (-1.82%)
EYE : 35.57 (+1.51%)
Medtronic's (MDT) Brain Therapies Device Receives FDA Approval

Medtronic (MDT) strengthens its robotics platform with the receipt of regulatory approval and the subsequent upgradation of its enabling technology portfolio.

HAE : 110.06 (-4.80%)
MDT : 120.97 (-0.10%)
RMD : 161.39 (-1.82%)
EYE : 35.57 (+1.51%)

Van Meerten Stock Picks

My 5 Favorite Mid Caps
Summary 100% technical buy signals with current momentum.
CRUS +2.85 , SEDG +0.27 , THC +0.11 , TER +2.87 , LITE +0.17
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar